1. Study Participant Flow
John R. Crouse et al. JAMA 2007;297:

2. Baseline Characteristics
John R. Crouse et al. JAMA 2007;297:

3. Lipid and Lipoprotein Parameters at Baseline and During Treatment
John R. Crouse et al. JAMA 2007;297:

4. Changes in the Primary and Secondary End Points
John R. Crouse et al. JAMA 2007;297:

5. Change in Maximum Carotid Intima-Media Thickness (CIMT) for the Primary End Point
John R. Crouse et al. JAMA 2007;297:

6. Commonly Reported Treatment-Emergent Adverse Events in Safety Population
John R. Crouse et al. JAMA 2007;297: